Telix Pharmaceuticals (ASX:TLX) has announced that the US FDA has accepted its Biologics License Application for its breakthrough investigational kidney cancer PET imaging agent TLX250-CDx (Zircaix, 89ZrDFO-girentuximab). …
US FDA accepts application for Telix's Zircaix and grants priority review
February 26, 2025 Australian Biotech
Latest Video
New Stories
-
Syntara receives FDA guidance for amsulostat in myelofibrosis treatment
August 11, 2025 - - Australian Biotech -
Noxopharm advances HERACLES trial for novel autoimmune disease drug
August 11, 2025 - - Australian Biotech -
Could the realities of AI quickly date or even swamp the HTA Review outcomes?
August 11, 2025 - - Latest News -
We asked ChatGPT to produce a podcast script explaining the pros and cons of the HTA Review
August 10, 2025 - - Latest News -
PYC Therapeutics accelerates clinical progress of PYC-003 in PKD trial
August 10, 2025 - - Australian Biotech -
Neuren expands NNZ-2591 pipeline to include SYNGAP1-related disorder
August 10, 2025 - - Australian Biotech -
AI has to be seen as a generational opportunity to get medicines to patients faster
August 10, 2025 - - Latest News